Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.

Related Keywords

Mansoorr Mirza , ,Primary Advanced ,Recurrent Endometrial Cancer ,Placebo Controlled Randomized Phase ,Dostarlimab ,Endometrial Cancer ,Chemotherapy ,Advanced Endometrial Cancer ,Primary Advanced Endometrial Cancer ,Placebo Controlled ,Engot En6 Nsgo ,Gog 3031 ,Ruby ,Ruby Trial ,Ruby Study ,Ruby Endometrial Cancer ,Ruby Endometrial Carcinoma ,